|Chairman of the Board
Representative Executive Officer, Executive Chairman
|Shinichi founded Sosei in June 1990 as a technology transfer company, having built up a wealth of experience during his years in the industry. He graduated from Tokyo University with an M.S. in Biochemistry and a major in Cultural Anthropology, going on to work in various positions in Planning and Development at Fujisawa Pharmaceutical Co. Ltd.
Shinichi was later appointed Representative Director (CEO) of Genentech Limited (Genentech Inc's Japan subsidiary). He has advised various companies including Genentech, GenPharm, Geron, IDEC, Pharmacyclics, and Vernalis, and played an important role in completing several significant deals.
Representative Executive Officer, CEO
|Peter has more than two decades of experience in the pharmaceutical industry encompassing strategic and operational leadership expertise across global geographies, functions and business segments. He had a 23-year career at GlaxoSmithKline, where he held multiple senior roles including General Manager of China, Head of Global Marketing and Senior VP of International Commercial Operations. From 2009, he has been a consultant specialising in supporting strategic growth opportunities in small- and medium-sized innovation-based life science companies; Syngene, a subsidiary of Biocon, Asia's largest biotechnology company; and Kromek Ltd, an AIM-listed company. He is also Non-executive Chairman of Fermenta Biotech Ltd, a subsidiary of DIL, a Mumbai-listed company. Peter completed his B.Sc Combined Honours in Physiology/ Zoology from Sheffield University.|
|Tomohiro is a partner at TMI Associates, which he co-founded in October 1990.
Tomohiro entered the Legal Training and Research Institute, Supreme Court of Japan in April 1978 and registered with Dai-ichi Tokyo Bar Association in April 1980. He joined Nishimura and Sanada Law Office in April 1980, becoming a partner in August 1985. He has also held positions at law firms Mason & Sloane, LLP. USA., Pollock, Bloom & Dekom, USA, and Pryor, Cashman, Sherman & Flynn, USA.
Tomohiro has been Outside Director of Nippon Shikizai, Inc. since November 1999, Outside Statutory Auditor of WOWOW INC. since June 2016, and Outside Director of Trust Capital Co., Ltd. since May 2016. He joined the External Board of Sosei Group Corporation in 2010.
|Julia P. Gregory received her M.B.A. from The Wharton School of The University of Pennsylvania and her B.A. in International Affairs with a minor in International Economics from George Washington University's Elliott School of International Affairs where she was elected to Phi Beta Kappa. She is currently Chairman and CEO of Isometry Advisors, Inc., a biotechnology financial and management advisory firm, has 16 years of biotechnology executive management experience and 20 years of investment banking experience. As an executive, she successfully raised more than $1.5 billion for her companies through initial public offerings, public and private offerings and creative strategic alliances with GlaxoSmithKline, BristolMyers Squibb, Takeda Pharmaceuticals, Genentech, (Roche) and Human Genome Sciences (GSK), among others. Recently, she was CEO of ContraFect Corporation, which focused on new biologics as an alternative to antibiotics. Prior to ContraFect, she was CEO of FivePrime Therapeutics, where she led a clinical-stage, biotechnology company discovering and developing innovative protein and antibody therapeutics in oncology and immunology; and was EVP, Head of Corporate Development and CFO of Lexicon Pharmaceuticals which identified the function of 5,000 genes, resulting in more than 100 protein targets with therapeutic potential in a range of diseases and a recently commercialized drug for carcinoid syndrome diarrhea. She is currently on the board of directors of Iconic Therapeutics and is an Advisor Partner to the Morgan Stanley Expansion Capital Fund.|
|Kuniaki has over 40 years’ experience at leading chemical and pharmaceutical companies in Japan. From 1975-2009, he was at Mitsubishi Chemical Holdings Corporation, where he held several leadership roles including Executive Officer and Head of Healthcare Strategy Office, and Head of Healthcare Planning. He is currently an Adviser to Mitsubishi Chemical Corporation.
From 2009, Kuniaki was at Mitsubishi Tanabe Pharma in Board and senior executive roles, including Representative Director, Senior Managing Executive Officer, General Manager of Research Division and International Business Department.
In 2014 he was appointed President and Representative Director of The KAITEKI Institute, Inc.
[Kuniaki was elected to the Sosei Group Board of Directors in June 2018.]
|David is an experienced scientist and physician, with a distinguished career in the pharmaceutical industry, most notably as Senior Vice President and Head of R&D for Pfizer in Europe.
He is currently President of R&D at Summit Therapeutics plc, an international clinical-stage company listed on AIM in the UK and NASDAQ in the US.
David has previously served as the Chief Operating Officer and Director of Scientific Translation at the Francis Crick Institute in London (2014 – 2017). Prior to this, he was Head of Research and Chief Medical Officer for Europe R&D at Pfizer Inc. from 2008 to 2011 and was Head of Therapy Area for Anti-infectives at Bayer AG from 1997 to 1999. He is a co-founder and Non-executive Chairman of RCP Pharma LLP.
David has a degree in biochemistry from University College London and qualified in Medicine from St George’s Hospital, London. He is a Fellow of the Royal College of Physicians and a Fellow of the Faculty of Pharmaceutical Medicine and honorary Professor of Medicine at Swansea University and Professor of Translational Medicine at St George’s.
[David was elected to the Sosei Group Board of Directors in June 2018.]
|Chairman of the Board
Representative Executive Officer, Chief Executive Chairman
Representative Executive Officer, CEO
|Executive Vice President, Chief R&D Officer|
|Former Visiting Professor of Biochemistry at Imperial College, London
Former Head of the Molecular Sciences Division of Glaxo Wellcome Inc. (present Glaxo Smithkline plc.)
Former CEO of Inpharmatica Ltd.（present Galapagos NV)
Founder and CEO of Heptares Therapeutics Ltd.
|Chief Medical Officer and VP of Development|
|Tim is a physician and clinical pharmacologist with more than 30 years of industry experience from both large pharmaceutical and small biotechnology companies. He spent over 20 years at GlaxoSmithKline and led all of its Phase 1 Clinical Research Units (in the US, UK, Europe and Australia), which supported the Centres of Excellence in Drug Discovery across all therapeutic areas. After GSK, he joined Evotec as Executive VP of Clinical Development, at which he was instrumental in advancing novel compounds to Phase 2 proof of concept studies. Dr Tasker then set up his own consulting firm providing high-level, early drug development expertise to companies in Europe, Australia and Japan. Dr Tasker is a Fellow of the UK Royal College of Physicians and of the UK Faculty of Pharmaceutical Medicine.
Tim is is Executive VP and Chief Medical Officer of Sosei Group Corporation.
|Executive Vice President, Corporate Administration and Group Chief Compliance Officer|
|Kazuhiko has more than 40 years of experience at corporate legal departments in the field of corporate transactions including M&A, offering and private placement of equity and debt securities, restructuring of group companies, compliance with the listing regulations of the stock exchanges in Japan and other countries, secretariat of the boards of directors, corporate governance and risk management. Prior to joining Sosei, he was Associate Senior Vice President and General Manager of NEC Fielding Co., Ltd. He graduated with an LL.B from Kyushu University in 1977 and with an MCL from The George Washington University Law School in 1984.|